Page last updated: 2024-12-08
nybomycin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
nybomycin: antibiotic substance produced by Streptomyces A 717; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 169159 |
CHEMBL ID | 1999880 |
SCHEMBL ID | 4326654 |
MeSH ID | M0046788 |
Synonyms (27)
Synonym |
---|
8,9-dihydro-4-(hydroxymethyl)-6,9-dimethyl-2,8-dioxopyrido(3,2-g)quinoline-1(2h)-carboxaldehyde |
nybomycin |
nsc613948 |
26326-47-6 |
nsc-613948 |
8-(hydroxymethyl)-6,11-dimethyl-4h-[1,3]oxazolo[5,4,3-ij]pyrido[3,2-g]quinoline-4,10(11h)-dione |
NCI60_004922 |
SCHEMBL4326654 |
unii-nlb430f005 |
nlb430f005 , |
30408-30-1 |
8-(hydroxymethyl)-6,11-dimethyl-4h-(1,3)oxazolo(5,4,3-ij)pyrido(3,2-g)quinoline-4,10(11h)-dione |
nsc 613948 |
nybomycin [mi] |
8-(hydroxymethyl)-6,11-dimethyl-2h,4h-oxazolo(5,4,3-ij)pyrido(3,2-g)quinoline-4,10(11h)-dione |
CHEMBL1999880 |
8-(hydroxymethyl)-6,11-dimethyl-2h,4h-oxazolo[5,4,3-ij]pyrido[3,2-g]quinoline-4,10(11h)-dione |
J-017950 |
Q27284932 |
8-(hydroxymethyl)-6,11-dimethyl-2h,4h-[1,3]oxazolo[5,4,3-ij]pyrido[3,2-g]quinoline-4,10(11h)-dione |
DTXSID40949186 |
6-(hydroxymethyl)-3,10-dimethyl-15-oxa-3,13-diazatetracyclo[7.6.1.02,7.013,16]hexadeca-1(16),2(7),5,8,10-pentaene-4,12-dione |
6-(hydroxymethyl)-3,10-dimethyl-15-oxa-3,13-diazatetracyclo[7.6.1.0?,?.0??,??]hexadeca-1(16),2(7),5,8,10-pentaene-4,12-dione |
HY-123635 |
CS-0084000 |
8-(hydroxymethyl)-6,11-dimethyl-4h-oxazolo[5,4,3-ij]pyrido[3,2-g]quinoline-4,10(11h)-dione |
AKOS040756181 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (29)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1231585 | Antibacterial activity against Mycobacterium smegmatis MC2 155 assessed as induction of morphological changes at 1 ug/ml after 48 hrs by phase contrast/scanning electron microscopic analysis | 2015 | Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13 | Anti-dormant mycobacterial activity and target analysis of nybomycin produced by a marine-derived Streptomyces sp. |
AID1617944 | Antibacterial activity against Escherichia coli ATCC 12435 after 16 to 48 hrs | 2019 | Journal of natural products, 12-27, Volume: 82, Issue:12 | Structure Determination, Functional Characterization, and Biosynthetic Implications of Nybomycin Metabolites from a Mining Reclamation Site-Associated |
AID1231597 | Inhibition of nybomycin probe (2) binding to pMV206 DNA (unknown origin) with cloned 700476 to 702854 bp of Mycobacterium bovis BCG genome overexpressed in Mycobacterium smegmatis ICHO1036 at 60 uM after 1 hr by agarose gel electrophoresis | 2015 | Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13 | Anti-dormant mycobacterial activity and target analysis of nybomycin produced by a marine-derived Streptomyces sp. |
AID1231579 | Antibacterial activity against Mycobacterium smegmatis MC2 155 under hypoxic condition after 96 hrs by MTT assay | 2015 | Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13 | Anti-dormant mycobacterial activity and target analysis of nybomycin produced by a marine-derived Streptomyces sp. |
AID1231590 | Antibacterial activity against Mycobacterium smegmatis ICHO1037 harboring pMV261 with cloned 4109204 to 4110235 bp of Mycobacterium bovis BCG genome at 2 ug/ml by agar plate method | 2015 | Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13 | Anti-dormant mycobacterial activity and target analysis of nybomycin produced by a marine-derived Streptomyces sp. |
AID1231591 | Antibacterial activity against Mycobacterium smegmatis ICHO1034 harboring pMV206 with cloned 685769 to 689308 bp of Mycobacterium bovis BCG genome at 4 ug/ml by agar plate method | 2015 | Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13 | Anti-dormant mycobacterial activity and target analysis of nybomycin produced by a marine-derived Streptomyces sp. |
AID1617945 | Antibacterial activity against Salmonella enterica ATCC 10708 after 16 to 48 hrs | 2019 | Journal of natural products, 12-27, Volume: 82, Issue:12 | Structure Determination, Functional Characterization, and Biosynthetic Implications of Nybomycin Metabolites from a Mining Reclamation Site-Associated |
AID1231589 | Antibacterial activity against Mycobacterium smegmatis ICHO1035 harboring pMV206 with cloned 696695 to 700844 bp of Mycobacterium bovis BCG genome at 2 ug/ml by agar plate method | 2015 | Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13 | Anti-dormant mycobacterial activity and target analysis of nybomycin produced by a marine-derived Streptomyces sp. |
AID1231596 | Antibacterial activity against Mycobacterium smegmatis ICHO2012 harboring pYUB415 with cloned 686465 to 716464 bp of Mycobacterium bovis BCG genome at 4 ug/ml by agar plate method | 2015 | Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13 | Anti-dormant mycobacterial activity and target analysis of nybomycin produced by a marine-derived Streptomyces sp. |
AID1231594 | Antibacterial activity against Mycobacterium smegmatis ICHO1037 harboring pMV261 with cloned 4109204 to 4110235 bp of Mycobacterium bovis BCG genome at 4 ug/ml by agar plate method | 2015 | Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13 | Anti-dormant mycobacterial activity and target analysis of nybomycin produced by a marine-derived Streptomyces sp. |
AID1617942 | Antibacterial activity against Bacillus subtilis ATCC 6633 after 16 to 48 hrs | 2019 | Journal of natural products, 12-27, Volume: 82, Issue:12 | Structure Determination, Functional Characterization, and Biosynthetic Implications of Nybomycin Metabolites from a Mining Reclamation Site-Associated |
AID1231578 | Antibacterial activity against Mycobacterium smegmatis MC2 155 under aerobic condition after 36 hrs by MTT assay | 2015 | Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13 | Anti-dormant mycobacterial activity and target analysis of nybomycin produced by a marine-derived Streptomyces sp. |
AID1231588 | Antibacterial activity against Mycobacterium smegmatis ICHO2012 harboring pYUB415 with cloned 686465 to 716464 bp of Mycobacterium bovis BCG genome at 2 ug/ml by agar plate method | 2015 | Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13 | Anti-dormant mycobacterial activity and target analysis of nybomycin produced by a marine-derived Streptomyces sp. |
AID1231586 | Antibacterial activity against Mycobacterium smegmatis ICHO1034 harboring pMV206 with cloned 685769 to 689308 bp of Mycobacterium bovis BCG genome at 2 ug/ml by agar plate method | 2015 | Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13 | Anti-dormant mycobacterial activity and target analysis of nybomycin produced by a marine-derived Streptomyces sp. |
AID1231584 | Antibacterial activity against Mycobacterium tuberculosis T1538 under aerobic condition after 7 days by MTT assay | 2015 | Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13 | Anti-dormant mycobacterial activity and target analysis of nybomycin produced by a marine-derived Streptomyces sp. |
AID1231580 | Antibacterial activity against Mycobacterium bovis BCG under aerobic condition after 7 days by MTT assay | 2015 | Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13 | Anti-dormant mycobacterial activity and target analysis of nybomycin produced by a marine-derived Streptomyces sp. |
AID1231593 | Antibacterial activity against Mycobacterium smegmatis ICHO1036 harboring pMV206 with cloned 700476 to 702854 bp of Mycobacterium bovis BCG genome at 4 ug/ml by agar plate method | 2015 | Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13 | Anti-dormant mycobacterial activity and target analysis of nybomycin produced by a marine-derived Streptomyces sp. |
AID1231587 | Antibacterial activity against Mycobacterium smegmatis ICHO1036 harboring pMV206 with cloned 700476 to 702854 bp of Mycobacterium bovis BCG genome at 2 ug/ml by agar plate method | 2015 | Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13 | Anti-dormant mycobacterial activity and target analysis of nybomycin produced by a marine-derived Streptomyces sp. |
AID1617941 | Antibacterial activity against Micrococcus luteus ATCC 15307 after 16 to 48 hrs | 2019 | Journal of natural products, 12-27, Volume: 82, Issue:12 | Structure Determination, Functional Characterization, and Biosynthetic Implications of Nybomycin Metabolites from a Mining Reclamation Site-Associated |
AID1231595 | Antibacterial activity against Mycobacterium smegmatis ICHO1038 harboring pMV261 with cloned 4126836 to 4129396 bp of Mycobacterium bovis BCG genome at 4 ug/ml by agar plate method | 2015 | Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13 | Anti-dormant mycobacterial activity and target analysis of nybomycin produced by a marine-derived Streptomyces sp. |
AID1231583 | Antibacterial activity against Mycobacterium tuberculosis T1413 under aerobic condition after 7 days by MTT assay | 2015 | Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13 | Anti-dormant mycobacterial activity and target analysis of nybomycin produced by a marine-derived Streptomyces sp. |
AID1231592 | Antibacterial activity against Mycobacterium smegmatis ICHO1035 harboring pMV206 with cloned 696695 to 700844 bp of Mycobacterium bovis BCG genome at 4 ug/ml by agar plate method | 2015 | Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13 | Anti-dormant mycobacterial activity and target analysis of nybomycin produced by a marine-derived Streptomyces sp. |
AID1617947 | Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by alamar blue assay | 2019 | Journal of natural products, 12-27, Volume: 82, Issue:12 | Structure Determination, Functional Characterization, and Biosynthetic Implications of Nybomycin Metabolites from a Mining Reclamation Site-Associated |
AID1617940 | Antibacterial activity against Staphylococcus aureus ATCC 6538 after 16 to 48 hrs | 2019 | Journal of natural products, 12-27, Volume: 82, Issue:12 | Structure Determination, Functional Characterization, and Biosynthetic Implications of Nybomycin Metabolites from a Mining Reclamation Site-Associated |
AID1231581 | Antibacterial activity against Mycobacterium bovis BCG under hypoxic condition after 14 days by MTT assay | 2015 | Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13 | Anti-dormant mycobacterial activity and target analysis of nybomycin produced by a marine-derived Streptomyces sp. |
AID1231582 | Antibacterial activity against Mycobacterium tuberculosis H37Rv under aerobic condition after 7 days by MTT assay | 2015 | Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13 | Anti-dormant mycobacterial activity and target analysis of nybomycin produced by a marine-derived Streptomyces sp. |
AID1617946 | Antifungal activity against Saccharomyces cerevisiae ATCC 204508 after 16 to 48 hrs | 2019 | Journal of natural products, 12-27, Volume: 82, Issue:12 | Structure Determination, Functional Characterization, and Biosynthetic Implications of Nybomycin Metabolites from a Mining Reclamation Site-Associated |
AID1617948 | Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 72 hrs by alamar blue assay | 2019 | Journal of natural products, 12-27, Volume: 82, Issue:12 | Structure Determination, Functional Characterization, and Biosynthetic Implications of Nybomycin Metabolites from a Mining Reclamation Site-Associated |
AID1617943 | Antibacterial activity against Mycobacterium aurum ATCC 23366 after 16 to 48 hrs | 2019 | Journal of natural products, 12-27, Volume: 82, Issue:12 | Structure Determination, Functional Characterization, and Biosynthetic Implications of Nybomycin Metabolites from a Mining Reclamation Site-Associated |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (12)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 4 (33.33) | 18.7374 |
1990's | 1 (8.33) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 7 (58.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 23.23
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (23.23) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 12 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |